In a laboratory at the University of Alabama in Huntsville, chemist Victor Ogungbe has begun a five-year, federally backed effort to bring a class of experimental antiviral compounds nearer to use in people. The target is a family of mosquito-borne alphaviruses, pathogens that have long lacked any approved vaccine or treatment. The work reflects a familiar human pattern: patient, incremental science aimed at a threat that has been neglected until it reaches a crisis. Its deeper question is whether an early intervention can spare the brain the damage that these infections can inflict.
UAH Chemist Leads $3.67M NIH Project on Alphavirus Treatments and Blood-Brain Barrier Protection
Molecular scissors the virus needs to reproduce and spread
Mark
Start with the basics. What is this grant actually paying for?
Mimi
Five years and $3.67 million to develop small molecules that block an alphavirus protein called nsP2 protease, the viral scissors that cut proteins so the virus can replicate.
Mark
And why does the blood-brain barrier come into it?
Mimi
Severe infection can inflame and loosen that barrier, which may contribute to brain swelling. The team wants to know if stopping the virus early keeps the barrier intact.
Luke
Let me be careful here. What has actually been shown so far?
Mimi
The compounds inhibited replication in cell cultures and protected mice from infection. That's the foundation.
Luke
So barrier protection is a question, not a result. And "proof-of-concept" is Ogungbe's own description.
Mimi
Right. Testing barrier protection is one of the two stated goals of this project.
Mark
Why organ-on-a-chip rather than animals?
Mimi
Ogungbe says it allows repeated sampling on both sides of the barrier, which is costly and technically limiting in animals, especially across many inhibitors and doses.
Luke
Worth noting that's his assessment of the method, and there's no human trial timeline in the reporting. Nobody should read this as a treatment being near.
Mimi
Fair. It's a long-term effort to build the evidence for one.
Il Polso
- A $3.67 million, five-year NIH grant has set a team in Huntsville to push experimental antivirals toward the clinic.
- Mosquito-borne alphaviruses still have no approved vaccine or treatment, leaving a real gap in human defenses.
- The compounds jam the viral protease nsP2, the molecular scissors the virus needs to copy and spread itself.
- Earlier cell-culture and mouse results are promising, and now the team is testing whether the drugs can keep the blood-brain barrier intact.
- Organ-on-a-chip models offer a cheaper, more detailed way to watch the barrier under treatment, though no human trial date has been set.
In a laboratory at the University of Alabama in Huntsville, chemist Victor Ogungbe has begun a five-year, federally backed effort to bring a class of experimental antiviral compounds nearer to use in people. The target is a family of mosquito-borne alphaviruses, pathogens that have long lacked any approved vaccine or treatment. The work reflects a familiar human pattern: patient, incremental science aimed at a threat that has been neglected until it reaches a crisis. Its deeper question is whether an early intervention can spare the brain the damage that these infections can inflict.
At the University of Alabama in Huntsville, chemist Victor Ogungbe, an associate professor and alumnus, has begun a five-year, $3.67 million project supported by the National Institutes of Health. The goal is to move a group of experimental antiviral compounds closer to clinical use against alphaviruses, a family of mosquito-borne viruses for which no vaccine or treatment is approved for people.
The team's compounds are designed to block viral replication by disabling nsP2, a protease that works like molecular scissors, cutting viral proteins into the pieces the virus needs to multiply. Earlier work showed these compounds stop replication in cell cultures and protect mice, so the project builds on a proof of concept. Its two main aims are to strengthen the potency of lead compounds, guided by animal testing, and to learn whether the drugs can preserve the blood-brain barrier, which infection-driven inflammation can break down. George Mason University professor Aarthi Narayanan is collaborating on the work.
To study this, the researchers will use organ-on-a-chip models that mimic human barrier tissue and allow repeated sampling that animal studies make difficult. Ogungbe also hopes the work will strengthen biodefense countermeasures that can be scaled up quickly. Over the coming years the team will refine promising compounds and examine nsP2's role in disease, though no timeline for human trials has been announced.
At the University of Alabama in Huntsville, chemist Victor Ogungbe has begun a five-year, $3.67 million project funded by the National Institutes of Health. Its aim is to move a class of experimental antiviral compounds closer to clinical development, against a family of mosquito-borne viruses for which no vaccine or treatment is currently approved for human use.
Ogungbe is an associate professor of chemistry and a UAH alumnus. UAH is part of The University of Alabama System. The grant is an R01 award, a form of NIH support that gives researchers sustained funding to test new approaches and generate evidence that can advance medicine and public health. The viruses in question are alphaviruses.
The team is working with small-molecule compounds designed to block viral replication. They target the protease domain of nonstructural protein 2, known as nsP2, which plays an important role in how alphaviruses reproduce. The protease acts something like molecular scissors, cutting proteins into the pieces the virus needs to multiply and spread. If the compounds can disable it, the virus cannot copy itself in that way.
The project does not start from zero. Earlier findings showed that the compounds inhibit alphavirus replication in cell cultures and protect mice against infection. Ogungbe calls this a well-established proof-of-concept. What sets his approach apart, he says, is a tight focus on advancing highly selective nsP2 protease inhibitors, drawn from a chemical space that is synthetically accessible, modular and scalable.
The team has two main objectives. The first is to improve the potency of lead compounds through structure-activity relationship studies, guided by efficacy testing in animal models. The second is to find out whether the compounds can help preserve the integrity of the blood-brain barrier during alphavirus infection. Professor Aarthi Narayanan of George Mason University is collaborating on the work.
The blood-brain barrier regulates what passes between the bloodstream and the brain, shielding it from harmful substances and pathogens. In severe viral infections, inflammation can compromise that barrier and make it more permeable, which may contribute to brain swelling and other neurological injury. The researchers want to learn whether intervening early with an antiviral can limit that damage, and so point toward ways of reducing the neurological consequences of these infections.
To test this, they will use organ-on-a-chip models of the blood-brain barrier, laboratory systems that replicate key features of human tissue. Ogungbe says they allow repeated sampling on both sides of the barrier to check permeability and viral particle levels, something that is very costly and technically limiting in animal models. That matters most when several inhibitors must be evaluated at different doses over extended periods.
There is a biodefense dimension as well. Ogungbe says he hopes to expand the countermeasures toolbox for pathogenic select agents and to develop medical interventions that can be scaled up quickly if needed. Over the coming years the team will refine promising compounds, evaluate their protective effects and deepen understanding of nsP2's role in alphavirus pathogenicity. No timeline for human trials has been given.
Citazioni salienti
We hope to expand the biodefense countermeasures toolbox for pathogenic select agents and develop medical interventions that can be scaled up quickly if and when needed.— Victor Ogungbe, UAH associate professor of chemistry
Vuoi la storia completa?
Leggi l'originale su News-Medical ↗
Education